MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT

The review takes into consideration the novel data on heart failure treatment: application of mineralocorticoid antagonists. The pathogenetic points are highlighted that are proved by clinical trials, as epidemiological concerns. Further opportunites are sketched for this special kind of treatment b...

Full description

Bibliographic Details
Main Authors:	V. N. Soboleva, E. O. Taratukhin
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2015-01-01
Series:	Российский кардиологический журнал
Subjects:	aldosterone mineralocorticoids cardiovascular mortality myocardial infarction eplerenone spironolactone
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/212

Similar Items

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
by: Shuhui Zhai, et al.
Published: (2024-09-01)

THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION
by: N. T. Vatutin, et al.
Published: (2019-07-01)

The use of mineralocorticoid receptor antagonists in the treatment of heart failure: a literature review
by: Árpád Kormányos, et al.
Published: (2024-08-01)

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis
by: Ahmed Elshahat, et al.
Published: (2024-09-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

Heart failure: the role for mineralocorticoid receptor antagonists
by: Bertram Pitt
Published: (2014-05-01)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
by: Houry Puzantian, et al.
Published: (2024-12-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex
by: Naoto Kuyama, et al.
Published: (2024-09-01)

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE
by: Yu. M. Lopatin, et al.
Published: (2015-08-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
by: A. G. Evdokimova, et al.
Published: (2023-01-01)

Successful lateralization by adrenal vein sampling in a patient of primary aldosteronism on concurrent mineralocorticoid receptor antagonist: Time to change the narrative
by: Rujul Jain, et al.
Published: (2024-09-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

The The Impact of Dapagliflozin on Aldosterone Hormone in Rats with Heart Failure
by: Skala Mamand Jawhar, et al.
Published: (2023-09-01)

EVIDENCE-BASED USE OF EPLERENONE
by: S. R. Gilyarevski, et al.
Published: (2014-07-01)

The role of mineralocorticoid receptors hyperactivation in the development of cardiorenal complications in patients with diabetes mellitus, perspective of the selective nonsteroidal mineralocorticoid receptors antagonist’s treatment: A review
by: Irina N. Bobkova
Published: (2023-11-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01)

Eight weeks of treatment with mineralocorticoid receptor blockade does not alter vascular function in individuals with and without type 2 diabetes
by: Stine H. Finsen, et al.
Published: (2024-04-01)

Research progress on the effects of mineralocorticoid receptor on cardiovascular diseases
by: MA Qian-yu, PENG Shi, ZHANG Zhao-yuan, ZHANG Dan, ZHANG Jin
Published: (2022-08-01)

Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial
by: Diogo Santos‐Ferreira, et al.
Published: (2024-02-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
by: Kisho Miyasako, et al.
Published: (2024-12-01)

Myosin Light Chain Phosphatase Plays an Important Role in Cardiac Fibrosis in a Model of Mineralocorticoid Receptor‐Associated Hypertension
by: Zhe Ye, et al.
Published: (2024-03-01)

Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure
by: Fang‐Fei Wei, et al.
Published: (2024-12-01)

Spironolactone Reduces the Risk of Death in Veterans With Heart Failure With Preserved Ejection Fraction
by: Katherine E. Kurgansky, et al.
Published: (2024-07-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

Effectiveness of Spironolactone in Reducing Osteoporosis and Future Fracture Risk in Middle-Aged and Elderly Hypertensive Patients
by: Song S, et al.
Published: (2024-06-01)

The Effects of Aldosterone on Hypertension-Associated Kidney Injury in a Tg-hAS Mouse Model
by: Huiying Gu, et al.
Published: (2024-12-01)

Chemokine receptor CXCR7 antagonism ameliorates cardiac and renal fibrosis induced by mineralocorticoid excess
by: Bing H. Wang, et al.
Published: (2024-11-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
by: N. A. Nuritdinov, et al.
Published: (2020-12-01)

The Impact of Heart Failure Chronic Treatment Prior to Cardiac Transplantation on Early Outcomes
by: Dragos-Florin Baba, et al.
Published: (2024-11-01)

Diuretic effects of Hecogenin and Hecogenin acetate via aldosterone synthase inhibition
by: Abdulmohsin J. Alamoudi, et al.
Published: (2024-07-01)

Effectiveness and safety of mineralocorticoid receptor antagonists in heart failure patients with and without diabetes: a systematic review and meta-analysis
by: Arga Setyo Adji, et al.
Published: (2024-11-01)

Hyponatremia in babies: a 11-year single-center study
by: Xu Liu, et al.
Published: (2024-06-01)

Adverse Effects of Aldosterone: Beyond Blood Pressure
by: Jenifer M. Brown
Published: (2024-04-01)

Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension
by: Zdeněk Ramík, et al.
Published: (2024-12-01)

ALDOSTERONE ANTAGONISTS. MODERN VIEWS ON THE MECHANISM OF ACTION AND EFFECTS OF SPIRONOLACTONE
by: V. I. Podzolkov, et al.
Published: (2017-05-01)

Eplerenone, a mineralocorticoid receptor inhibitor, reduces cirrhosis associated changes of hepatocyte glucose and lipid metabolism
by: Mohammad Mohabbulla Mohib, et al.
Published: (2024-12-01)

A Trial of Finerenone in a Patient with Primary Aldosteronism
by: Sandra Karanović Štambuk
Published: (2024-09-01)

Identification of a Novel CYP11B2 Variant in a Family with Varying Degrees of Aldosterone Synthase Deficiency
by: Mark R. Garrelfs, et al.
Published: (2024-03-01)

Hyperglycemia Potentiates Prothrombotic Effect of Aldosterone in a Rat Arterial Thrombosis Model
by: Anna Gromotowicz-Poplawska, et al.
Published: (2021-02-01)